Table 1.

Characteristics of the studies included in the systematic review

References	Year	Age (years)	Follow-up	Treatment/control, no.	Treatment	Control	Disease severity	Contents	Outcome measures
Singer [29]	2018	0.3–3.8	42 days or until follow-up appointment	14/16	Daily educational text messages	Standard care	Unclear	Disease burden; precipitators; skin care	(1) EASI
Liang [27]	2018	4–14	6 months	293/249	Four weekly lectures	Unclear	Moderate to severe	Long-term management, food allergy, psychological management, skin care	(1) SCORAD; (2) IDQOL, CDLQI; (3) Knowledge assessment questionnaire
Pustisek [25]	2016	0.25–12	2 months	64/64	One-time lecture with written material	Standard care	Moderate to severe	Precipitators, diet, diagnosis and treatment, skin care, quality of life impacts and managements, practical session	(1) SCORAD; (2) FDLQI; (3) STAI and PPS
Staab [20]	2006	0.25–7	12 months	274/244	Six weekly group sessions	Standard care	Moderate to severe	Basic medical information, psychological management, food allergy and nutrition, skin care	(1) SCORAD and PO-SCORAD; (2) Parents’ quality of life questionnaire; (3) Itch questionnaires JUCKKI and JUCKJU as age indicated
		8–12		102/83
		13–18		70/50
Futamura [21]	2013	0.5–6	6 months	29/30	Two continuous days of group meeting with information booklet	Standard care and information booklet	Moderate to severe	Basic medical information, treatments and adverse effects, allergen and avoidance, skin care	(1) SCORAD and PO-SCORAD; (2) Questionnaire on scores for pruritus, sleeplessness and corticosteroid anxiety; (3) DFI
Grillo [28]	2006	0–16	12 weeks	32/29	One-time workshop	Standard care	Unlimited	Basic medical information, precipitators, skin care, practical session	(1) Objective SCORAD; (2) DFI, CDLQI, and IDQOL
Shaw [23]	2008	0–18	The 1 or 3 month follow-up appointment determined by severity	51/55	One-time individualized education	Unclear	Unlimited	Medical treatment, skin care, allergen avoidance, pruritus reliefs, lifestyle managements	(1) SCORAD; (2) CDLQI, and IDQOL
Chinn [30]	2002	0.5–4	12 weeks	55/42	One-time session	Unclear	Unclear	Basic medical information; treatment application; skin care	(1) CDLQI or IDQOL and DFI
		4–16		50/50
Weber [22]	2008	2–16	24 months	16/16	Fortnightly support group for 6 months	Unclear	Moderate to severe	Overview of the disease and treatment followed by discussion	(1) CDLQI and DFI; (2) McGill pain questionnaire for pruritus assessment
Moore [26]	2009	< 16	4 weeks	49/50	One-time individual consultation with information booklets	Standard care	Unlimited	Basic medical information, precipitator avoidance, treatments and information booklet	(1) SCORAD
Schuttelaar [24]	2010	< 4	12 months	37/34	One-time group session or education during individual follow-up visits	Standard care	Unlimited	Basic medical information, allergies, skin care, practical session and written action plan	(1) SCORAD and objective SCORAD; (2) CDLQI or IDQOL and DFI; (3) Program satisfaction
		4–16		35/35
Saritha [31]	2018	0–16	6 weeks	5/5	Video on AD	Video on a placebo topic	Unclear	Unclear	(1) Topical steroid phobia and adherence; (2) EASI
Park [32]	2017	0.3–4.3	1 week	10/11	One-time video tape with tailored leaflet	Same video tape without tailored leaflet	Mild to moderate	Skin care and tailored ideal amount of moisturizer	(1) Moisturizer usage; (2) EASI

EASI eczema area and severity index, SCORAD Scoring of Atopic Dermatitis, CDLQI Children’s Dermatology Life Quality Index, IDQOL Infants’ Dermatology Quality of Life Index, DLQI Dermatology Life Quality Index, PO-SCORAD Patient Oriented SCORAD; FDLQI Family Dermatitis Life Quality Index, STAI State Trait Anxiety Inventory, PPS Perceived Stress Scale, DLQI Dermatitis Life Quality Index, QoLIAD Quality of Life Index for Atopic Dermatitis, BDI Beck Depression Inventory, EQ-5D EuroQol 5-Dimension, POEM patient-oriented eczema measure, HADS-D Hospital Anxiety and Depression Score, DFI Dermatitis Family Impact, RCT randomized control trial, JUCKKI/JUCKJU Itching cognitions questionnaires